24/7 Market News Snapshot 23 December, 2024 – Traws Pharma, Inc. Common Stock (NASDAQ:TRAW)

December 23, 2024

DENVER, Colo., 23 December, 2024 (247marketnews.com) – (NASDAQ:TRAW) are discussed in this article.
Traws Pharma, Inc. (NASDAQ:TRAW) is experiencing a remarkable surge in its stock price, currently trading at $10.732, reflecting a dramatic increase of 113.78% from the previous day’s close at $5.020. This significant rise is sparked by heightened investor interest and confidence, as demonstrated by a robust trading volume of 990.60K shares exchanged. Analysts are closely monitoring TRAW’s performance to determine if it can sustain this momentum, suggesting a potentially transformative period for the company.

In addition to market enthusiasm, Traws Pharma has announced promising advancements in its investigational therapy, tivoxavir marboxil, which targets H5N1 avian influenza. The company recently completed Phase 1 dosing among healthy volunteers, revealing a favorable safety and tolerability profile. Importantly, the therapy maintains effective plasma drug levels for over 23 days, indicating its potential as both a treatment and preventive measure against the virus.

Tivoxavir marboxil has demonstrated significant efficacy in preclinical studies against various strains of avian influenza, including resistant variants. Noteworthy results from a particular in vivo study showed complete protection of mice exposed to H5N1 from a human case and considerable suppression of viral replication in lung tissues post-treatment. These findings highlight the compound’s potential role in addressing the increasing threat of bird flu to human health, a concern that health officials are vigilantly monitoring.

Dr. Werner Cautreels, CEO of Traws Pharma, emphasized the company’s dedication to expanding its influenza program in response to the urgent need for effective treatments. With plans to initiate a Phase 2 trial in the first half of 2025, Traws Pharma aims to position tivoxavir marboxil as a significant therapeutic option in the ongoing battle against viral infections, reaffirming its commitment to meeting critical health challenges.

Related news for (TRAW)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.